» Articles » PMID: 11703589

Dysregulation of LDL Receptor Under the Influence of Inflammatory Cytokines: a New Pathway for Foam Cell Formation

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2001 Nov 13
PMID 11703589
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lipid-mediated renal injury is an important component of glomerulosclerosis and its similarity to atherosclerosis is well described. This study focused on the relationship between lipid-mediated injury and inflammation by examining the role of inflammatory cytokines in the regulation of human mesangial cell low-density lipoprotein (LDL) receptors.

Methods: A human mesangial cell line (HMCL) was used to study the effects of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) on the regulation of LDL receptor mRNA and protein in the presence of a high concentration of native LDL (250 microg/mL).

Results: Native LDL caused foam cell formation in HMCL in the presence of antioxidants, TNF-alpha and IL-1beta. Both cytokines overrode LDL receptor suppression induced by a high concentration of LDL and increased LDL uptake by enhancing receptor expression. These cytokines also caused increased expression of SCAP [sterol responsive element binding protein (SREBP) cleavage activation protein], and an increase in the nuclear translocation of SREBP, which induces LDL receptor expression.

Conclusion: These observations demonstrate that inflammatory cytokines can modify cholesterol-mediated LDL receptor regulation in mesangial cells, permitting unregulated intracellular accumulation of unmodified LDL and causing foam cell formation. These findings suggest that inflammatory cytokines contribute to lipid-mediated renal damage, and also may have wider implications for the study of inflammation in the atherosclerotic process.

Citing Articles

Lc-ms-based untargeted metabolomics reveals potential mechanisms of histologic chronic inflammation promoting prostate hyperplasia.

Li J, Wu B, Fan G, Huang J, Li Z, Cao F PLoS One. 2024; 19(12):e0314599.

PMID: 39715183 PMC: 11666064. DOI: 10.1371/journal.pone.0314599.


Lipid metabolism disorder in diabetic kidney disease.

Han Y, Du B, Zhu X, Wang Y, Zheng H, Liu W Front Endocrinol (Lausanne). 2024; 15:1336402.

PMID: 38742197 PMC: 11089115. DOI: 10.3389/fendo.2024.1336402.


Unraveling the Crosstalk between Lipids and NADPH Oxidases in Diabetic Kidney Disease.

Njeim R, Alkhansa S, Fornoni A Pharmaceutics. 2023; 15(5).

PMID: 37242602 PMC: 10222020. DOI: 10.3390/pharmaceutics15051360.


Prognostic value of lipid profile in adult hemophagocytic lymphohistiocytosis.

Cheng W, Wang L, Gao X, Duan L, Shu Y, Qiu H Front Oncol. 2023; 13:1083088.

PMID: 36895490 PMC: 9988898. DOI: 10.3389/fonc.2023.1083088.


Renal UTX-PHGDH-serine axis regulates metabolic disorders in the kidney and liver.

Chen H, Liu C, Wang Q, Xiong M, Zeng X, Yang D Nat Commun. 2022; 13(1):3835.

PMID: 35788583 PMC: 9253056. DOI: 10.1038/s41467-022-31476-0.